2023-03-16 16:50:36 ET
- Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q4 GAAP EPS of -$0.57 misses by $0.03 .
- Revenue of $2.69M (-19.9% Y/Y) misses by $1.73M .
- Selling, General and Administrative expenses were $8.3 million and $29.1 million for fourth quarter and full year 2022, respectively, as compared to $6.0 million and $23.9 million for the same periods in 2021.
-
Cash, cash equivalents, and short-term debt securities as of December 31, 2022 totaled $98.9 million compared to $106.1 million as of December 31, 2021.
-
As of December 31, 2022, the Company had 44,074,284 common shares outstanding.
For further details see:
Eiger BioPharmaceuticals GAAP EPS of -$0.57 misses by $0.03, revenue of $2.69M misses by $1.73M